<?xml version='1.0' encoding='utf-8'?>
<document id="24788408"><sentence text="Effect of verapamil on the pharmacokinetics of pasireotide in healthy volunteers."><entity charOffset="10-19" id="DDI-PubMed.24788408.s1.e0" text="verapamil" /><entity charOffset="47-58" id="DDI-PubMed.24788408.s1.e1" text="pasireotide" /><pair ddi="false" e1="DDI-PubMed.24788408.s1.e0" e2="DDI-PubMed.24788408.s1.e0" /><pair ddi="false" e1="DDI-PubMed.24788408.s1.e0" e2="DDI-PubMed.24788408.s1.e1" /></sentence><sentence text="We evaluated the drug-drug interaction between pasireotide SC and verapamil, a known P-glycoprotein inhibitor" /><sentence text=" Subjects received pasireotide SC (single dose, 600 μg) on day 1, and samples for pharmacokinetics evaluation were collected from days 1 to 8" /><sentence text=" Subjects received an oral dose of verapamil 240 mg/d for 10 days (days 15-24)"><entity charOffset="35-44" id="DDI-PubMed.24788408.s4.e0" text="verapamil" /></sentence><sentence text=" On day 18, subjects also received pasireotide SC 600 μg" /><sentence text=" Pharmacokinetic sampling for pasireotide SC and verapamil was done during days 18 to 25 and days 15 to 21, respectively"><entity charOffset="49-58" id="DDI-PubMed.24788408.s6.e0" text="verapamil" /></sentence><sentence text=" Safety evaluations were performed throughout the study period, including a 30-day post-treatment follow-up" /><sentence text=" Pharmacokinetic profiles of pasireotide SC alone and in combination with verapamil sustained-release (SR) were superimposable with the geometric mean ratios (90% confidence interval [CI]) of 0"><entity charOffset="74-83" id="DDI-PubMed.24788408.s8.e0" text="verapamil" /></sentence><sentence text="98 (0" /><sentence text="91-1" /><sentence text="06) for C(max), 0" /><sentence text="97 (0" /><sentence text="90-1" /><sentence text="04) for AUC(last), and 0" /><sentence text="98 (0" /><sentence text="92-1" /><sentence text="05) for AUC(inf)" /><sentence text=" Exploratory analyses showed a 17% (90% CI, 0"><entity charOffset="40-42" id="DDI-PubMed.24788408.s18.e0" text="CI" /></sentence><sentence text="72-0" /><sentence text="94) reduction in C(trough) and 31% (0" /><sentence text="58-0" /><sentence text="82) reduction in C(max) (8 hours post-dose) for verapamil SR with pasireotide SC versus verapamil alone" /><sentence text=" Pasireotide SC with or without verapamil was well tolerated"><entity charOffset="1-12" id="DDI-PubMed.24788408.s23.e0" text="Pasireotide" /><entity charOffset="32-41" id="DDI-PubMed.24788408.s23.e1" text="verapamil" /><pair ddi="false" e1="DDI-PubMed.24788408.s23.e0" e2="DDI-PubMed.24788408.s23.e0" /><pair ddi="false" e1="DDI-PubMed.24788408.s23.e0" e2="DDI-PubMed.24788408.s23.e1" /></sentence><sentence text=" In conclusion, there was no change in the rate of pasireotide absorption and elimination or extent of exposure following concomitant administration with verapamil"><entity charOffset="51-62" id="DDI-PubMed.24788408.s24.e0" text="pasireotide" /><entity charOffset="154-163" id="DDI-PubMed.24788408.s24.e1" text="verapamil" /><pair ddi="false" e1="DDI-PubMed.24788408.s24.e0" e2="DDI-PubMed.24788408.s24.e0" /><pair ddi="false" e1="DDI-PubMed.24788408.s24.e0" e2="DDI-PubMed.24788408.s24.e1" /></sentence><sentence text="" /></document>